After a bitter fight, activist boots Progenics directors—and eyes a CEO swap next

exit
Three of Progenics' directors could be out the door after activist investor Velan's picks were reportedly given the vote of approval from shareholders. (iStock)

Progenics' board of directors has fought bitterly against activist investor Velan Capital, going so far as to sell out rather than lose the battle. Now, Velan reportedly has the shareholder votes to complete its revamp of the drugmaker's board––but the fight's not over yet. 

A majority of Progenics' shareholders gave their written consent to push CEO Mark Baker and directors David Scheinberg and Nicole Williams off the board in favor of five of Velan's hand-picked directors, the private equity firm said Friday.

Velan's nominees include Gérard Ber, David Mims, Ann MacDougall, Heinz Mäusli and Eric Ende. Two Progenics directors, Dr. Karen Ferrante and Bradley Campbell, would stay on under the new leadership, Velan said. But the activist aims to replace Baker as CEO as well as kick him off the board.

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Progenics said in a statement the written consent votes had been submitted to an independent inspector and both companies would be allowed to "challenge the validity" of the votes before a final decision is reached. 

"The Company does not anticipate commenting further on the consents until the inspector has completed its tabulation and both parties have had the opportunity to review and challenge consents and revocations," Progenics said. 

Velan managing partner Bala Venkataraman said in a statement the vote would provide "fresh perspectives" on Progenics' intended merger with Lantheus Medical Imaging and its strategic plan. 

RELATED: Proxy adviser ISS backs ouster of Progenics CEO in activist battle

Suggested Articles

AbbVie, Roche and Johnson & Johnson are working to show Venclexta can combine with Imbruvica in frontline chronic lymphocytic leukemia.

Incyte and Novartis' Jakafi is eying a nod in chronic graft vs. host disease—and it may just have the data to get it done.

With a slate of vaccine authorizations on the horizon, vaccine execs from a trio of leading shot makers are looking at distribution hurdles ahead.